Advertisement

Effect of the Glucagon-like Peptide-1 Mimetic on Ion- and Osmoregulating Renal Functions in Normoglycemia and Hyperglycemia

  • 5 Accesses

Abstract

Incretins are hormones with a wide range of biological activity. We studied the ratio of the glycemic effect of the glucagon-like peptide-1 mimetic and its effect on the renal excretion of sodium and water. It was found that both effects depend on the initial blood concentration of glucose. In normoglycemia, exenatide had no effect on blood sugar level, but it significantly increased urinary sodium excretion and reabsorption of solute-free water. In hyperglycemia the blood glucose concentration was normalized by exenatide, while the excretion of sodium by the kidneys and the reabsorption of solute-free water were increased to a small extent. This pattern was found both in patients with type 2 diabetes mellitus and in rats with hyperglycemia induced by intraperitoneal injection of glucose.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

REFERENCES

  1. 1

    Shestakova, M.V. and Vikulova, O.K., Modern pharmacotherapy of type 2 diabetes using analogues of glucagon-like peptide-1 (GLP-1), Sakharnyi Diabet, 2007, no. 1, p. 9.

  2. 2

    Holst, J.J., Deacon, C.F., Vilsboll, T., et al., Glucagon-like peptide-1, glucose homeostasis and diabetes, Trends Mol. Med., 2008, vol. 14, no. 4, p. 161.

  3. 3

    Galstyan, G.R., Karataeva, E.A., and Yudovich, E.A., Evolution of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes, Sakharnyi Diabet, 2017, vol. 20, no. 4, p. 286.

  4. 4

    Biryukova, E.V. and Yakubova, T.R., Byetta: past, present, and future, Eff. Farmakoter., 2015, no. 11, p. 34.

  5. 5

    Gallwitz, B., Novel therapeutic approaches in diabetes, Endocrinol. Dev., 2016, vol. 31, p. 43.

  6. 6

    Nauck, M.A. and Meier, J.J., Incretin hormones: their role in health and disease, Diabetes Obes. Metab., 2018, vol. 20, suppl. 1, p. 5.

  7. 7

    Natochin, Yu.V., Marina, A.S., and Kutina, A.V., The role of incretin as an integrator of sodium and water balance regulation, Dokl. Biol. Sci., 2014, vol. 458, no. 1, p. 271.

  8. 8

    Crajoinas, R.O., Oricchio, F.T., Pessoa, T.D., et al., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1, Am. J. Physiol. Renal Physiol., 2011, vol. 301, no. 2, p. F355.

  9. 9

    Kutina, A.V., Golosova, D.V., Marina, A.S., et al., Role of Vasopressin in the regulation of renal sodium excretion: interaction with glucagon-like peptide-1, J. Neuroendocrinol., 2016, vol. 28, no. 4. https://doi.org/10.1111/jne.12367

  10. 10

    Shutskaya, Zh.V., Shakhmatova, E.I., Kuznetsova, A.A., and Natochin, Yu.V., The role of the kidneys in the regulation of osmolality and concentrations of cations in the blood serum in hyperglycemia, Hum. Physiol., 2008, vol. 34, no. 5, p. 601.

  11. 11

    Shakhmatova, E.I., Pimenova, E.V., and Shutskaya, Zh.V., The influence of Byetta (Exenatide) on the osmoregulatory function of the kidneys in humans with diabetes mellitus, Eksp. Klin. Farmakol., 2014, vol. 77, no. 3, p. 24.

  12. 12

    De Vogel-van den Bosch, J., Hoeks, J., Timmers, S., et al., The effects of long- or medium-chain fat diets on glucose tolerance and myocellular content of lipid intermediates in rats, Obesity, 2011, vol. 19, no. 4, p. 792.

  13. 13

    Tonneijck, L., Smits, M.M., Muskiet, M.H., et al., Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomized, double-blind, placebo-controlled trial, Diabetologia, 2016, vol. 59, no. 7, p. 1412.

  14. 14

    Tonneijck, L., Smits, M.M., Muskiet, M.H., et al., Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial, Diabetes Care, 2016, vol. 39, no. 11, p. 2042.

  15. 15

    von Scholten, B.J., Hansen, T.W., Goetze, J.P., et al., Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes, J. Diabetes Complications, 2015, vol. 29, no. 5, p. 670.

  16. 16

    Skov, J., Pedersen, M., Holst, J.J., et al., Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial, Diabetes Obes. Metab., 2016, vol. 18, no. 6, p. 581.

  17. 17

    Muskiet, M.H., Tonneijck, L., Smits, M.M., et al., Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men, Diabetes Obes. Metab., 2016, vol. 18, no. 2, p. 178.

  18. 18

    Schlatter, P., Beglinger, C., Drewe, J., and Gutmann, H., Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells, Regul. Pept., 2007, vol. 141, no. 1–3, p. 120.

  19. 19

    Thomson, S.C., Kashkouli, A., and Singh, P., Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat, Am. J. Physiol. Renal Physiol., 2013, vol. 304, no. 2, p. F137.

  20. 20

    Roscoe, J.M., Halperin, M.L., Rolleston, F.S., and Goldstein, M.B., Hyperglycemia-induced hyponatremia: metabolic considerations in calculation of serum sodium depression, Can. Med. Assoc. J., 1975, vol. 112, no. 4, p. 452.

  21. 21

    Mozaffari, M.S. and Schaffer, S.W., Impaired saline-stimulated diuresis and natriuresis in the conscious hypertensive glucose-intolerant rat, Am. J. Hypertens., 2002, vol. 15, no. 1, p. 58.

  22. 22

    Marwaha, A. and Lokhandwala, M.F., Diminished natriuretic response to dopamine D1 receptor agonist, SKF-38393 in obese Zucker rats, Clin. Exp. Hypertens., 2003, vol. 25, no. 8, p. 509.

  23. 23

    Arumugam, S., Sreedhar, R., Miyashita, S., et al., Comparative evaluation of torasemide and furosemide on rats with streptozotocin-induced diabetic nephropathy, Exp. Mol. Pathol., 2014, vol. 97, no. 1, p. 137.

  24. 24

    Brands, M.W. and Manhiani, M.M., Sodium-retaining effect of insulin in diabetes, Am. J. Physiol.-Regul. Integr. Comp. Physiol., 2012, vol. 303, no. 11, p. R1101.

  25. 25

    Ueda-Nishimura, T., Niisato, N., Miyazaki, H., et al., Synergic action of insulin and genistein on Na+/K+/2Cl cotransporter in renal epithelium, Biochem. Biophys. Res. Commun., 2005, vol. 332, no. 4, p. 1042.

  26. 26

    Chavez-Canales, M., Arroyo, J.P., Ko, B., et al., Insulin increases the functional activity of the renal NaCl cotransporter, J. Hypertens., 2013, vol. 31, no. 2, p. 303.

  27. 27

    Blazer-Yost, B.L., Esterman, M.A., and Vlahos, C.J., Insulin-stimulated trafficking of ENaC in renal cells requires PI3-kinase activity, Am. J. Physiol., Cell. Physio-l., 2003, vol. 284, p. C1645.

  28. 28

    Irsik, D.L., Blazer-Yost, B.L., Staruschenko, A., and Brands, M.W., The normal increase in insulin after a meal may be required to prevent postprandial renal sodium and volume losses, Am. J. Physiol.-Regul. Integr. Comp. Physiol., 2017, vol. 312, no. 6, p. R965.

Download references

Author information

Correspondence to A. V. Kutina.

Ethics declarations

Conflict of interests. The authors declare that they have no conflict of interest connected with the publication of this article.

Statement on the welfare of animals. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Statement of compliance with standards of research involving humans as subjects. All procedures performed in studies involving human participants were in accordance with the biomedical ethics principles formulated in the 1964 Helsinki Declaration and its later amendments and approved by the bioethics commission of the Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences (St. Petersburg). Informed consent was obtained from all individual participants involved in the study after their being explained the potential risks and advantages, as well as the essence of the future study.

Additional information

Translated by E. Babchenko

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kutina, A.V., Balbotkina, E.V., Karavashkina, T.A. et al. Effect of the Glucagon-like Peptide-1 Mimetic on Ion- and Osmoregulating Renal Functions in Normoglycemia and Hyperglycemia. Hum Physiol 45, 685–692 (2019) doi:10.1134/S036211971904008X

Download citation

Keywords:

  • hyperglycemia
  • glucagon-like peptide-1
  • sodium
  • solute-free water
  • kidney
  • diabetes mellitus
  • exenatide